OS Therapies Inc (OSTX): Shareholders' Equity

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2024-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$6.10M

As of 2025-12-31

-$11.91M

As of 2026-06-30

2023-12-31 Shareholders' Equity (USD) 2025-12-31

Period ended	Shareholders' Equity	Change YoY	Source filing
2025-12-31	-$6.10M	n/m	2026-03-31, Balance as of period end
2024-12-31	-$3.27M	n/c	2026-03-31, Balance as of period end
2023-12-31	-$24.02M	n/a	2025-03-31, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Shareholders' Equity	Change YoY
OS Therapies Inc (OSTX)	2025-12-31	-$6.10M	n/m
Serina Therapeutics, Inc. (SER)	2025-12-31	-$37.0K	n/m
CV Sciences, Inc. (CVSI)	2025-12-31	$1.47M	-18.2%
Adial Pharmaceuticals, Inc. (ADIL)	2025-12-31	$5.28M	+29.7%
Cannapharmarx, Inc. (CPMD)	2025-12-31	-$30.15M	n/m
Kairos Pharma, Ltd. (KAPA)	2025-12-31	$6.34M	+32.8%
Vyome Holdings, Inc (HIND)	2025-12-31	$3.76M	n/m
Matinas BioPharma Holdings, Inc. (MTNB)	2025-12-31	$4.83M	-36.4%
Telomir Pharmaceuticals, Inc. (TELO)	2025-12-31	$5.91M	+819.6%

Compare OSTX, SER, CVSI, ADIL side by side · Screen every company in Pharmaceutical Preparations ↗